Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Malignant Melanoma

Free Subscription 15.12.2025 2 Am J Dermatopathol 1 Biochem Biophys Res Commun 1 Br J Cancer 1 Br J Dermatol 1 Clin Cancer Res 1 Int J Cancer 3 J Am Acad Dermatol 3 JAMA 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Dermatopathol

1. MAAROUF S, Alomari AK
   A Challenging Diagnosis of Primary Cutaneous Melanoma With Rhabdomyosarcomatous Differentiation: A Case Study and Review of the Literature.
   Am J Dermatopathol. 2025 Dec 4. doi: 10.1097/DAD.0000000000003181.
   PubMed         Abstract available
   
   
2. TAUZIEDE-ESPARIAT A, Poilane C, Gleize D, Bouvier B, et al
   BRAFV600E and NRASQ61R Antibodies Are Sensitive and Specific Diagnostic Biomarkers for BRAF and NRAS Mutations in Conjunctival Melanomas.
   Am J Dermatopathol. 2025 Dec 8. doi: 10.1097/DAD.0000000000003183.
   PubMed        
   
   

   
   Biochem Biophys Res Commun

3. ZHANG W, Xu Q, Sui Y
   Targeting DHODH promoter G-quadruplex to induce ferroptosis in melanoma cells.
   Biochem Biophys Res Commun. 2025;795:153117.
   PubMed         Abstract available
   
   

   
   Br J Cancer

4. BERTHOD G, Cisarovsky C, Petrova T, Decosterd LA, et al
   Sorafenib plus selective internal radiotherapy with (90)Y resin microspheres for the treatment of uveal melanoma with liver metastasis: a phase I trial.
   Br J Cancer. 2025 Dec 11. doi: 10.1038/s41416-025-03279.
   PubMed         Abstract available
   
   

   
   Br J Dermatol

5. ZHAO P, Chew C, Szeto P, Berry W, et al
   Genomic copy number burden distinguishes the diagnosis and prognosis of primary dermal melanoma.
   Br J Dermatol. 2025 Dec 9:ljaf507. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Clin Cancer Res

6. RAMELYTE E, Kott J, Lawless AR, Ciernik A, et al
   Circulating tumor DNA is prognostic of patient outcome and enables therapy monitoring in metastatic uveal melanoma.
   Clin Cancer Res. 2025 Dec 12. doi: 10.1158/1078-0432.CCR-25-2274.
   PubMed         Abstract available
   
   

   
   Int J Cancer

7. NAESER Y, Mikiver R, Isaksson K, Lambe M, et al
   Characteristics and overall survival in patients with T1 melanoma: A nationwide matched cohort study.
   Int J Cancer. 2025 Dec 12. doi: 10.1002/ijc.70287.
   PubMed         Abstract available
   
   

   
   J Am Acad Dermatol

8. NUSRAT F, Lauck K, Jennings T, Lawrence N, et al
   Longitudinal Risk of Cutaneous Squamous Cell Carcinoma Development Following PD-1 Inhibitor Therapy for Melanoma: A Retrospective TriNetX Cohort Study.
   J Am Acad Dermatol. 2025 Dec 11:S0190-9622(25)03378.
   PubMed        
   
   
9. MILLER JR 3RD, Nelson J, Leachman SA, Yu W, et al
   Applying Patient-Centered Methodology to Melanoma Patients from the National Cancer Database to Predict More Accurately Their Sentinel Lymph Node Biopsy Outcome.
   J Am Acad Dermatol. 2025 Dec 10:S0190-9622(25)03373.
   PubMed        
   
   
10. NUGENT ST, Deitermann AM, Lin SK, Lewis DJ, et al
    Response to Gill et al., "Response to Factors associated with adherence to skin self-examination recommendations for melanoma patients: a prospective cohort study".
    J Am Acad Dermatol. 2025 Dec 6:S0190-9622(25)03275.
    PubMed        
    
    

    
    JAMA

11. JOSHI UM, Kashani-Sabet M, Kirkwood JM
    A Review of Melanoma-Reply.
    JAMA. 2025 Dec 11. doi: 10.1001/jama.2025.20510.
    PubMed        
    
    
12. YU C, Chen R, Shan H
    A Review of Melanoma.
    JAMA. 2025 Dec 11. doi: 10.1001/jama.2025.20512.
    PubMed        
    
    
13. MITRA D, Bishop AJ, Guadagnolo BA
    A Review of Melanoma.
    JAMA. 2025 Dec 11. doi: 10.1001/jama.2025.20514.
    PubMed        
    
    

    
    PLoS One

14. LIANG S, Sun T, Jia X, Cao J, et al
    Systematic analysis of non-melanoma skin cancer burden: A comparative study between China and the world from 1990 to 2021 and prediction to 2036.
    PLoS One. 2025;20:e0333960.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.